Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
86 hedge funds and large institutions have $346M invested in Oxford Immunotec Global PLC Ordinary Shares in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 20 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
20% more capital inflows, than outflows
Capital inflows: $78.4M | Capital outflows: $65.5M
2.7% more ownership
Funds ownership: 91.67% → 94.37% (+2.7%)
7% less funds holding
Funds holding: 92 → 86 (-6)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$15.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$14.2M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$8.05M |
| 4 |
First Light Asset Management
Edina,
Minnesota
|
+$6.07M |
| 5 |
Renaissance Technologies
New York
|
+$4.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$18.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.25M |
| 3 |
Man Group
London,
United Kingdom
|
-$6.14M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.55M |
| 5 |
Consonance Capital Management
New York
|
-$4.06M |
OXFD Hedge Fund Activity: Q2 2019 in Review
86 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q2 2019, worth a combined $346M — down 18% from $420M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of OXFD and 16 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 35 added.
The largest buyer was Millennium Management, adding an estimated $15.5M. The largest seller was BlackRock, cutting an estimated $18.6M.
- 86 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q2 2019, down from 92 in Q1 2019.
- Funds reported $346M of Oxford Immunotec Global PLC Ordinary Shares stock for Q2 2019, down 18% quarter-over-quarter.
- 16 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q2 2019 and 20 closed out, a net change of -4 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q2 2019 was Millennium Management, an estimated $15.5M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q2 2019 was BlackRock, an estimated $18.6M sold.
Based on aggregated 13F filings for Q2 2019.